NATCO Pharma Share Price Target 2025: Amid the fluctuations in the stock market, shares of NATCO Pharma remain in focus after a brokerage firm, Nirmal Bang, has maintained a ‘Hold’ rating and revised its target to Rs 1,044. The brokerage says the company struggled in Q3, with revenues and margins falling sharply due to no sales of Revlimid in the US and a decline in its domestic business.
NATCO Pharma Share Price Today – February 17, 2025
On Monday, February 17, 2025, shares of NATCO Pharma is trading -1.25% lower at Rs 872.20 on the NSE as compared to its last closing price of Rs 883.20. The shares have been trading within a price range of Rs 861.90 – 903.15. During the session, the total trading volume was 1,060,252 shares. The 52-week high level for NATCO Pharma company stock is Rs 1,639.00, whereas the 52-week low is Rs 861.90.
NATCO Pharma Share Price Target 2025 – Nirmal Bang
CMP: Rs 872.20 | Price Target: Rs 1,044 | Upside: 20%
Nirmal Bang has given a ‘Hold’ rating on NATCO Pharma stock with a target price of Rs 1,044. Analysts observed that NATCO Pharma’s Q3 performance was weaker than expectations, with both revenue and EBITDA margins coming under pressure.
The company revenue fell 38%, due to the absence of Revlimid sales in the US market and a decline in the domestic formulations business. EBITDA fell 86% and margins also shrunk 27% due to increased R&D expenses.
Nirmal Bang is still cautious about NATCO Pharma as the entire growth depends on the performance of Revlimid and CTPR. Apart from these two, there is nothing visible in the US market nor is there any strong momentum on the domestic side. For this reason the brokerage has given a ‘Hold’ rating.
NATCOPHARM: Stock Overview Table
NATCO Pharma Performance Overview
(Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Figw.in We advise investors to check with certified experts before making any investment decisions.)